Timothy Cloughesy
#105,451
Most Influential Person Now
American neurologist
Timothy Cloughesy's AcademicInfluence.com Rankings
Timothy Cloughesymedical Degrees
Medical
#1385
World Rank
#1718
Historical Rank
Neurology
#132
World Rank
#198
Historical Rank
Timothy Cloughesyphilosophy Degrees
Philosophy
#5047
World Rank
#7759
Historical Rank
Logic
#2388
World Rank
#3372
Historical Rank
Download Badge
Medical Philosophy
Timothy Cloughesy's Degrees
- Doctorate Medicine University of California, San Francisco
Why Is Timothy Cloughesy Influential?
(Suggest an Edit or Addition)According to Wikipedia, Timothy Frances Cloughesy is a professor of Clinical Neurology and director of the Neuro-Oncology Program at the University of California, Los Angeles. He is an expert on the treatment of brain cancer.
Timothy Cloughesy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010) (2448)
- Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (2009) (2276)
- Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. (2014) (1957)
- Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. (2005) (1455)
- Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma (2007) (1052)
- High-throughput oncogene mutation profiling in human cancer (2007) (1041)
- Gene Expression Profiling of Gliomas Strongly Predicts Survival (2004) (735)
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma (2018) (711)
- Standards of care for treatment of recurrent glioblastoma--are we there yet? (2013) (582)
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma (2008) (568)
- Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment (2005) (484)
- Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. (2008) (472)
- Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. (2011) (455)
- Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. (2003) (449)
- Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. (2005) (441)
- Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015) (438)
- Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 (2006) (428)
- Glioblastoma: from molecular pathology to targeted treatment. (2014) (417)
- Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. (2011) (410)
- Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA (2014) (403)
- Adult Glioblastoma. (2017) (403)
- Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. (2007) (401)
- 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. (2006) (400)
- Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme (2005) (389)
- MR imaging correlates of survival in patients with high-grade gliomas. (2005) (386)
- Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. (2008) (375)
- Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. (2016) (370)
- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) (367)
- Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target (2006) (357)
- Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain (2006) (345)
- Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies (2010) (338)
- mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. (2013) (329)
- An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. (2011) (326)
- Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. (2009) (325)
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (2018) (321)
- Gene expression profiling identifies molecular subtypes of gliomas (2003) (312)
- EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy (2009) (305)
- Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation (2013) (300)
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 (2018) (299)
- Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. (2012) (290)
- Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma (2015) (288)
- Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma (2000) (281)
- Identification of molecular subtypes of glioblastoma by gene expression profiling (2003) (280)
- A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. (2010) (271)
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy (2012) (265)
- Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach (2010) (261)
- Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. (2011) (258)
- The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers (2009) (257)
- Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma (2012) (250)
- Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. (2006) (244)
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. (2015) (244)
- Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. (1999) (243)
- MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy (2006) (241)
- Primary Glioblastomas Express Mesenchymal Stem-Like Properties (2006) (235)
- Targeted Molecular Therapy of GBM (2003) (235)
- Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma (2009) (234)
- Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials (2017) (232)
- Bevacizumab and chemotherapy for recurrent glioblastoma (2009) (230)
- A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. (2006) (223)
- The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis (2009) (216)
- Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. (2009) (215)
- DNA-microarray analysis of brain cancer: molecular classification for therapy (2004) (215)
- Distinct transcription profiles of primary and secondary glioblastoma subgroups. (2006) (213)
- Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age (2008) (206)
- Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. (2011) (204)
- The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. (2014) (193)
- An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. (2016) (190)
- Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. (2008) (182)
- AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme (2011) (176)
- 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. (2015) (176)
- Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. (2002) (174)
- Toward precision medicine in glioblastoma: the promise and the challenges. (2015) (173)
- mTOR signaling in glioblastoma: lessons learned from bench to bedside (2010) (170)
- Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma (2011) (170)
- Probabilistic Radiographic Atlas of Glioblastoma Phenotypes (2013) (165)
- Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells (2008) (160)
- EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. (2015) (158)
- Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma (2009) (157)
- Correlation of 6-18F-Fluoro-l-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas (2010) (156)
- Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. (2006) (155)
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. (2011) (154)
- Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. (2003) (153)
- Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. (2009) (153)
- Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study (2012) (150)
- Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. (2009) (149)
- A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) (2008) (148)
- Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. (2008) (148)
- Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. (2008) (146)
- Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma (2016) (145)
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. (2011) (145)
- Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma (1999) (144)
- Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. (2014) (140)
- Predicting major depression in brain tumor patients (2002) (139)
- Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. (2013) (138)
- PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors (2007) (136)
- Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors (2009) (135)
- Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). (2009) (134)
- Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma (2017) (133)
- Adaptive platform trials: definition, design, conduct and reporting considerations (2019) (132)
- Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. (2016) (132)
- 3′-Deoxy-3′-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab (2012) (132)
- Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. (2016) (131)
- Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line (2004) (128)
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. (2014) (127)
- 18F-FDOPA Kinetics in Brain Tumors (2007) (127)
- Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery (2011) (126)
- Differential Induction of Glioblastoma Migration and Growth by Two Forms of Pleiotrophin* (2005) (123)
- EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. (2013) (120)
- The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria (2014) (120)
- Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC (2018) (120)
- Genomic Landscape of Meningiomas (2009) (120)
- Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies (2012) (119)
- Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. (2010) (119)
- PD-1 blockade enhances the vaccination-induced immune response in glioma. (2016) (118)
- Clinical trial end points for high-grade glioma: the evolving landscape. (2011) (117)
- Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy (2013) (115)
- mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. (2017) (114)
- Time course of imaging changes of GBM during extended bevacizumab treatment (2008) (113)
- De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. (2013) (112)
- Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma (2020) (112)
- Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen (2003) (111)
- Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy (2014) (111)
- Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas (2012) (110)
- 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. (2012) (110)
- Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE (2017) (109)
- Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab (2011) (109)
- The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation (2010) (109)
- Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 (2007) (107)
- Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. (2012) (106)
- 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. (2009) (105)
- Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples (2008) (104)
- Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients (2013) (104)
- Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas (2017) (104)
- Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. (2013) (103)
- Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides (2000) (101)
- Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. (2015) (101)
- Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. (2011) (99)
- Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs (2004) (98)
- Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. (2013) (98)
- A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05) (2008) (98)
- Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. (2011) (96)
- Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. (2019) (96)
- Targeted therapy for malignant glioma patients: Lessons learned and the road ahead (2009) (96)
- Bevacizumab for newly diagnosed glioblastoma. (2014) (94)
- Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? (2011) (93)
- Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance (2015) (92)
- Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. (2010) (91)
- Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. (2012) (91)
- Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. (1997) (90)
- PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma (2013) (88)
- Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls (2012) (86)
- Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric (2013) (86)
- Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone (2009) (86)
- Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. (2013) (86)
- Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis. (2013) (86)
- Safety of anticoagulation use and bevacizumab in patients with glioma. (2008) (85)
- Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas (2014) (84)
- pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. (2015) (82)
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. (2017) (80)
- Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. (2004) (79)
- Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI (2013) (79)
- Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. (2012) (79)
- Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma (2007) (78)
- Mapping tumor growth rates in patients with malignant gliomas: A test of two algorithms (2000) (76)
- Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas. (2020) (76)
- Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. (2011) (75)
- A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas (2008) (75)
- The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? (2018) (75)
- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. (2019) (75)
- p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition (2004) (75)
- 18F-fluorothymidine kinetics of malignant brain tumors (2007) (74)
- Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. (2014) (74)
- Detection of immune responses after immunotherapy in glioblastoma using PET and MRI (2017) (71)
- Alien hand syndrome (1995) (71)
- Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. (2016) (71)
- Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. (2011) (71)
- Large-scale assessment of the gliomasphere model system. (2016) (69)
- Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)‐MRI estimates of cerebral blood volume (CBV) in human gliomas (2012) (69)
- Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. (2006) (68)
- Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy (2003) (68)
- Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab (2011) (66)
- Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). (2010) (66)
- Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy (2016) (66)
- Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases (2010) (66)
- Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma (2014) (65)
- Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. (2015) (64)
- A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme (2007) (64)
- Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study (2008) (63)
- Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma (2017) (62)
- Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. (2001) (61)
- Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. (2020) (60)
- EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells (2004) (60)
- The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. (2015) (60)
- Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. (2013) (60)
- Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. (2005) (60)
- Differential Gene Expression in Glioblastoma Defined by ADC Histogram Analysis: Relationship to Extracellular Matrix Molecules and Survival (2012) (60)
- Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial (2021) (59)
- Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. (2004) (58)
- Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept (2011) (57)
- Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. (2017) (57)
- Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials (2017) (57)
- Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. (2012) (56)
- Protective Properties of Radio-Chemoresistant Glioblastoma Stem Cell Clones Are Associated with Metabolic Adaptation to Reduced Glucose Dependence (2013) (56)
- PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies (2013) (56)
- The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab (2015) (56)
- NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. (2004) (55)
- Topographical and temporal specificity of human intraoperative optical intrinsic signals (1998) (55)
- Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 (2012) (55)
- Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. (1999) (55)
- Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 (2008) (55)
- Pros and cons of current brain tumor imaging. (2014) (55)
- Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. (2000) (54)
- NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI) (2015) (54)
- Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients (2012) (54)
- Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma (2017) (53)
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy (2017) (53)
- Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. (2015) (53)
- Regional and Voxel‐Wise Comparisons of Blood Flow Measurements Between Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC‐MRI) and Arterial Spin Labeling (ASL) in Brain Tumors (2014) (52)
- Kinetics of 3′-Deoxy-3′-18F-Fluorothymidine During Treatment Monitoring of Recurrent High-Grade Glioma (2010) (51)
- Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma (2018) (51)
- Initial treatment patterns over time for anaplastic oligodendroglial tumors. (2012) (51)
- Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients (2015) (50)
- Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma (2021) (50)
- Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy against Brain Tumors (2014) (50)
- A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs (2004) (50)
- Monitoring carotid test occlusions with continuous EEG and clinical examination. (1993) (49)
- A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. (2010) (49)
- Impact of 3,4-Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective (2012) (49)
- Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). (2014) (49)
- Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. (2000) (48)
- Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials (2017) (47)
- Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial (2022) (47)
- Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. (2012) (47)
- First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy (2019) (47)
- Nonlinear registration of diffusion‐weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab (2012) (47)
- 18F-FLT and 18F-FDOPA PET kinetics in recurrent brain tumors (2014) (46)
- Pharmacological blood-brain barrier modification for selective drug delivery (1995) (46)
- Prediction of Neurocognitive Outcome in Adult Brain Tumor Patients (2004) (46)
- Bevacizumab for recurrent ependymoma (2009) (46)
- Simulation, phantom validation, and clinical evaluation of fast pH‐weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST‐EPI) in glioma at 3 T (2016) (46)
- The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas (2013) (46)
- Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma (2011) (45)
- Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. (2018) (44)
- Intra-arterial carboplatin chemotherapy for brain tumors: A dose escalation study based on cerebral blood flow (1997) (43)
- Brain tumor treatment: chemotherapy and other new developments. (2004) (43)
- Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. (2010) (43)
- A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) (2019) (42)
- Contrast‐enhancing tumor growth dynamics of preoperative, treatment‐naive human glioblastoma (2016) (42)
- Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab (2011) (42)
- A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) (2019) (42)
- Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi‐passageable neurosphere formation (2010) (42)
- Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation (2018) (42)
- Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas (2015) (42)
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy (2017) (41)
- Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome (2005) (41)
- Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor Status in Glioblastoma (2015) (41)
- Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. (2013) (41)
- Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. (2016) (40)
- A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. (2004) (39)
- Lipid Droplets Maintain Energy Homeostasis and Glioblastoma Growth via Autophagic Release of Stored Fatty Acids (2020) (39)
- Novel brainstern syndrome associated with prostate carcinoma (1993) (39)
- Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells (2011) (38)
- Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance (2014) (38)
- A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. (2016) (38)
- Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update. (2017) (38)
- Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. (2008) (38)
- Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). (2013) (37)
- Irinotecan Treatment for Recurrent Malignant Glioma Using an Every-3-Week Regimen (2002) (37)
- Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma (2017) (37)
- Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. (2012) (37)
- Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. (2016) (37)
- Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma (2018) (36)
- Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma (2016) (36)
- Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. (2020) (36)
- Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data (2019) (36)
- Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). (2016) (36)
- Brain Tumor Immunotherapy (2000) (35)
- Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide (2015) (34)
- MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab (2015) (34)
- Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). (2013) (34)
- Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. (2005) (34)
- Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. (2001) (34)
- Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data. (2015) (33)
- Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma (2018) (33)
- The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. (2019) (32)
- Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02) (2007) (32)
- Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas (2014) (32)
- A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients (2005) (31)
- Prioritization schema for immunotherapy clinical trials in glioblastoma (2016) (31)
- Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. (2016) (31)
- Simultaneous pH‐sensitive and oxygen‐sensitive MRI of human gliomas at 3 T using multi‐echo amine proton chemical exchange saturation transfer spin‐and‐gradient echo echo‐planar imaging (CEST‐SAGE‐EPI) (2018) (31)
- Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas (2015) (30)
- Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)‐MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab (2016) (30)
- A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. (2011) (30)
- New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target? (2011) (29)
- Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. (2019) (29)
- Will kinase inhibitors make it as glioblastoma drugs? (2012) (29)
- Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII (2019) (29)
- ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION (2017) (29)
- AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas (2010) (28)
- Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). (2019) (28)
- Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high‐grade gliomas (2016) (28)
- Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. (2014) (27)
- An LXR agonist promotes GBM cell death through inhibition of an EGFR / AKT / SREBP-1 / LDLR-dependent pathway (2011) (27)
- Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009 (2007) (27)
- Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry (2019) (27)
- Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. (2018) (27)
- Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. (2015) (27)
- Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange (2016) (26)
- 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study (2018) (26)
- Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI (2015) (26)
- Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy. (2020) (26)
- Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. (2021) (26)
- Federated learning enables big data for rare cancer boundary detection (2022) (26)
- Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial. (2004) (25)
- The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma (2020) (25)
- pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma (2019) (25)
- Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab (2014) (25)
- Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. (2004) (25)
- Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug (2021) (24)
- Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio (2018) (24)
- Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage (2013) (23)
- First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma (2020) (22)
- FDA accelerated approval benefits glioblastoma. (2010) (22)
- Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study (2020) (22)
- Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids (2016) (22)
- It is time to include patients with brain tumors in phase I trials in oncology. (2011) (22)
- A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. (2002) (22)
- A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1. (2019) (21)
- A Prospective Blinded Study of the Predictive Value of an Extreme Drug Resistance Assay in Patients Receiving CPT-11 for Recurrent Glioma (2004) (21)
- Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study (2007) (21)
- Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma (2018) (21)
- Mapping Therapeutic Response in a Patient with Malignant Glioma (2001) (21)
- A gene expression signature predicts recurrence-free survival in meningioma (2018) (20)
- Striking the balance between PTEN and PDK1: it all depends on the cell context. (2009) (20)
- A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma (2020) (20)
- Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T (2019) (20)
- Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping (2015) (20)
- Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]). (2014) (19)
- Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma (2018) (19)
- Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02 (2017) (19)
- 18 F-fluorothymidine kinetics of malignant brain tumors (2007) (19)
- Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. (2014) (18)
- Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers. (2016) (18)
- A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas (2012) (18)
- 325ONivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM) (2017) (18)
- Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors. (2013) (18)
- Leveraging external data in the design and analysis of clinical trials in neuro-oncology. (2021) (18)
- Using molecular information to guide brain tumor therapy (2006) (17)
- Content Based Image Retrieval for MR Image Studies of Brain Tumors (2006) (17)
- ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192) (2018) (17)
- LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192) (2020) (17)
- Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study (2019) (17)
- ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS (2019) (16)
- Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. (2013) (16)
- Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation (2018) (16)
- Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. (2009) (16)
- A modeling-based factor extraction method for determining spatial heterogeneity of Ga-68 EDTA kinetics in brain tumors (1996) (16)
- mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma (2019) (16)
- Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. (2014) (16)
- ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (2021) (16)
- Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). (2009) (16)
- Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study (2017) (16)
- Bevacizumab for recurrent ependymoma. (2009) (16)
- Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. (2014) (16)
- LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (2019) (16)
- Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine (2017) (16)
- ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS (2016) (16)
- A modeling-based factor extraction method for determining spatial heterogeneity of Ga-68 EDTA kinetics in brain tumor (1996) (16)
- Imaging biomarkers for antiangiogenic therapy in malignant gliomas. (2013) (15)
- Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo (2018) (15)
- Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas (2020) (15)
- Glioblastoma therapy in the elderly: one age does not fit all. (2012) (14)
- A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. (2014) (14)
- To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. (2019) (14)
- Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma (2013) (14)
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). (2009) (14)
- Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma (2016) (14)
- Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. (2020) (14)
- MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting (2020) (14)
- Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) phase II study (2005) (14)
- Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma (2011) (14)
- A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. (2010) (14)
- Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment. (2017) (14)
- Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas (2017) (14)
- Discriminant Analysis of 18 F-Fluoro-Thymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma (2011) (13)
- Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1 (2021) (13)
- Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. (2015) (13)
- NovoTTF: where to go from here? (2017) (13)
- C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma (2014) (13)
- Topographic mapping of somatosensory evoked potentials helps identify motor cortex more quickly in the operating room (2005) (13)
- ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE (2019) (12)
- Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM). (2013) (12)
- Prolonged treatment with biologic agents for malignant glioma: A case study with high dose tamoxifen (1997) (12)
- Platform trials arrive on time for glioblastoma. (2018) (12)
- IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143. (2015) (12)
- AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. (2011) (11)
- Erratum: Genomic Landscape of Meningiomas (Brain Pathology (2010) 20 (751-762)) (2011) (11)
- ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION (2018) (11)
- ATIM-33. INTERIM RESULTS OF A PHASE II MULTI-CENTER STUDY OF ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192) (2019) (11)
- Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (2018) (11)
- Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. (2019) (11)
- Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08) (2006) (11)
- The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. (2009) (11)
- Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. (2020) (11)
- Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study (2022) (11)
- Synthesizing MR Image Contrast Enhancement Using 3D High-Resolution ConvNets (2021) (11)
- ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM) (2019) (10)
- ATIM-04. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAÏVE PATIENTS WITH RECURRENT GBM (2016) (10)
- Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. (2018) (10)
- Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143 (2022) (10)
- Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients (2018) (10)
- Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM). (2016) (10)
- High order diffusion tensor imaging in human glioblastoma. (2011) (10)
- Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. (2021) (10)
- Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas (2017) (10)
- A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. (2016) (10)
- ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM). (2017) (9)
- Ongoing clinical trials. (2003) (9)
- Considerations for uniform and accurate biospecimen labelling in a biorepository and research environment (2011) (9)
- INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. (2020) (9)
- OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study (2019) (9)
- Voxelwise and Patientwise Correlation of 18F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes (2020) (9)
- The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma. (2011) (9)
- 16 – Structural and Functional Imaging of Cerebral Neoplasia (2000) (9)
- Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET (2021) (9)
- Bevacizumab as first-line therapy for glioblastoma. (2012) (9)
- Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging (2018) (9)
- Phase II study of POLY-ICLC in recurrent anaplastic glioma-A North American Brain Tumor Consortium study. (2006) (9)
- GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. (2020) (8)
- Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. (2017) (8)
- PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. (2013) (8)
- Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma (2015) (8)
- Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma. (2003) (8)
- Gene expression profiling identifies molecular subtypes of gliomas (2006) (8)
- Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma (2014) (8)
- Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease. (2019) (8)
- AT-02INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584) (2014) (8)
- Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma. (2021) (7)
- Ipilimumab for recurrent glioblastoma (GBM). (2014) (7)
- Circulating Immune Cell and Outcome Analysis from the Phase 2 Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. (2022) (7)
- Somatostatin Receptor Ligand Therapy-A Potential Therapy for Neurocytoma. (2019) (7)
- Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy (2014) (7)
- Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
- Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
- Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04–03) (2007) (7)
- Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM (2015) (7)
- ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143 (2016) (7)
- Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. (2020) (7)
- Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB). (2014) (7)
- Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. (2022) (7)
- Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma (2021) (7)
- OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143 (2017) (7)
- Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. (2015) (6)
- Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas (2020) (6)
- D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant–Induced MIR148A Promoter Methylation (2018) (6)
- Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept (2013) (6)
- ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM) (2018) (6)
- Cancer Therapy : Preclinical The mTOR Kinase Inhibitors , CC 2141 and CC 2142 , Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas (2013) (6)
- Arsenic reverses glioblastoma resistance to mTOR-targeted therapies (2013) (6)
- Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience (2020) (6)
- Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab. (2014) (6)
- Treatment of Unresectable Adult Pilocytic Astrocytoma with Bevacizumab with or without Temozolomide (P04.183) (2012) (6)
- ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) (2018) (5)
- CLIN-ONGOING CLINICAL TRIALS (2012) (5)
- FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas (2021) (5)
- Interaction between sorafenib and erlotinib. (2009) (5)
- Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG). (2021) (5)
- Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. (2011) (5)
- PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1 (2019) (5)
- Automated MR image processing and analysis of malignant brain tumors: enabling technology for data mining (2007) (5)
- ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS (2017) (5)
- EGFR, the Lazarus target for precision oncology in glioblastoma. (2022) (5)
- 8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study (2009) (5)
- Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden (2021) (5)
- Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. (2020) (5)
- Emerging function of mTORC 2 as a core regulator in glioblastoma : metabolic reprogramming and drug resistance (2015) (5)
- Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab (2010) (5)
- CLIN-ONGOING CLINICAL TRIALS (2012) (5)
- Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma (2020) (5)
- SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation (2019) (5)
- PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM (2014) (5)
- Research report Robustness of gene expression profiling in glioma specimen samplings and derived cell lines (2005) (5)
- HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA (2013) (5)
- Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement (2020) (5)
- A novel bicompartmental mathematical model of glioblastoma multiforme. (2015) (5)
- NC-01ATTENTIONAL AND LANGUAGE FUNCTIONING IN ADULT PATIENTS WITH GLIOMA: A VOXEL-BASED LESION-SYMPTOM MAPPING STUDY. (2014) (5)
- Reply to W. Wick et al (2010) (5)
- Novel methodology for the archiving and interactive reading of clinical magnetic resonance spectroscopic imaging (2002) (4)
- Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation. (2011) (4)
- Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study. (2009) (4)
- Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series (2019) (4)
- Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). (2013) (4)
- ACTR-33. INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY (2019) (4)
- Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population. (2020) (4)
- RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA (2018) (4)
- IT-05ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION. (2014) (4)
- A Tool for Improving the Longitudinal Imaging Characterization for Neuro-Oncology Cases (2008) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- Efficacy and biomarker findings from AVaglio, a phase III trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma (2013) (4)
- Contrast-enhanced T1-weighted digital subtraction maps combined with diffusion MRI to identify recurrent glioblastoma patients that benefit from bevacizumab therapy. (2014) (4)
- Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation (2022) (4)
- ET-53IPILIMUMAB FOR RECURRENT GLIOBLASTOMA (GBM) (2014) (4)
- A retrospective single institutional analysis of bevacizumab and chemotherapy versus non-bevacizumab treatments for recurrent glioblastoma (2008) (4)
- Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas (2020) (4)
- Contrast-enhanced T1-weighted subtraction maps for response assessment in recurrent glioblastoma treated with bevacizumab. (2013) (4)
- Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas (2020) (4)
- Radiographic Read Paradigms and the Roles of the Central Imaging Laboratory in Neuro-Oncology Clinical Trials. (2020) (4)
- r ecurrent glioblastoma Treated with Bevacizumab: Contrast- enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a (2014) (4)
- Oncodiagnosis panel: 2002. Patient's symptoms not related to the lesion seen in the MR images. (2003) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- BI-22CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) (2014) (4)
- Hierarchical segmentation of malignant gliomas via integrated contextual filter response (2008) (4)
- Reply to comment on: ‘Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach’ (2016) (4)
- Assess treatment response using FDOPA PET in patients with recurrent malignant gliomas treated with bevacizumab and irinotecan (2008) (4)
- Biomarkers in NOA-04: another piece to the puzzle. (2016) (4)
- Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib. (2021) (4)
- Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma (2020) (4)
- A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma. (2018) (4)
- Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo. (2016) (4)
- Tumor suppressive miR-148 a is silenced by CpG island hypermethylation in IDH 1 mutant gliomas (2014) (4)
- In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays (2009) (4)
- ET-12PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA (2014) (3)
- Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium. (2016) (3)
- 26LBA Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma (2015) (3)
- Encouraging survival with Toca 511 and Toca FC compared to external lomustine control. (2016) (3)
- Abstract B265: A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma (2009) (3)
- Oncodiagnosis Panel: 2002 - Adult Central Nervous System Neoplasms (2003) (3)
- Dendritic cell vaccination in combination with TLR-7 agonist, imiquimod, following radio-chemotherapy for newly diagnosed glioblastoma (2007) (3)
- IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
- Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). (2015) (3)
- Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143. (2017) (3)
- Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas (2022) (3)
- Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI (2022) (3)
- Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. (2018) (3)
- Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. (2019) (3)
- ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL (2018) (3)
- “Aerobic glycolytic imaging” of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging (2021) (3)
- ATIM-19. RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (2018) (3)
- Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas? (2018) (3)
- Oncodiagnosis panel: 2002. Metastatic NSCLC. (2003) (3)
- Author Correction: Adaptive platform trials: definition, design, conduct and reporting considerations (2019) (3)
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O (2017) (3)
- During Treatment Monitoring of Recurrent High-Grade Glioma (2010) (3)
- ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM) (2019) (3)
- Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma. (2012) (3)
- Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. (2011) (3)
- ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) (2016) (2)
- Imaging biomarkers of ramucirumab and olaratumab in patients with recurrent glioblastoma. (2013) (2)
- Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. (2022) (2)
- Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors. (2022) (2)
- Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio. (2016) (2)
- PATH-35. MAINTENANCE OF EGFR ABNORMALITIES OVER TIME AND COMPARISON OF MOLECULAR METHODOLOGIES IN GLIOBLASTOMA (GBM) (2017) (2)
- Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital “Flipbooks” to Control Systems Theory (2022) (2)
- Metabolic imaging with 18F-FLT PET is a powerful predictor for overall survival in patients with malignant gliomas treated with bevacizumab and irinotecan (2007) (2)
- Prognostic value of 18F-FDOPA PET in treated low-grade gliomas with non-enhancing T2 changes on MRI (2013) (2)
- 8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study (2009) (2)
- Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. (2018) (2)
- EXTH-67. TG02, A BRAIN-PENETRANT MULTI-CDK INHIBITOR, POTENTLY SUPPRESSES MYC-DRIVEN GLIOBLASTOMA (2017) (2)
- ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION (2018) (2)
- Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group. (2020) (2)
- MEDICAL RADIATION THERAPIES (2013) (2)
- AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM]). (2014) (2)
- Impact of 18F-DOPA PET/CT imaging on the management of patients with brain tumors: The referring physician's perspective (2010) (2)
- Preferential tumor localization in relation to 18F-FDOPA uptake for lower‐grade gliomas (2021) (2)
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial (2023) (2)
- OS09.6 Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial (2017) (2)
- Use of bevacizumab to facilitate up-front chemoradiation in poor-risk patients with glioblastoma multiforme by improving neurologic function. (2010) (2)
- Imaging , Diagnosis , Prognosis Treatment Response Evaluation Using 18 F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy (2014) (2)
- ATIM-25. NEOADJUVANT PD-1 ANTIBODY BLOCKADE IS ASSOCIATED WITH FOCAL UPREGULATION OF PD-L1 AND CD8 T CELL INFILTRATE IN RECURRENT GLIOBLASTOMA (2018) (2)
- Abstract 3594: Adaptively randomized seamless-phase multiarm platform trial: Glioblastoma Multiforme Adaptive Global Innovative Learning Environment (GBM AGILE) (2017) (2)
- Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab (2020) (2)
- Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI) (2021) (2)
- Atnt-10Does Valproic Acid Improve Survival In Glioblastoma? A Meta-Analysis Of Randomized Trials In Newly Diagnosed Glioblastoma (2015) (2)
- Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. (2020) (1)
- Diagnosis and Management of Brain Stem Gliomas (1994) (1)
- Content-based Image Retrieval of Glioblastoma Multiforme (2007) (1)
- SYMPTOM MANAGEMENT/QUALITY OF LIFE (2013) (1)
- Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (2022) (1)
- The Dopamine Receptor Antagonist TFP Prevents Phenotype Conversion and Improves Survival in Mouse Models of Glioblastoma (2019) (1)
- 280O Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results (2022) (1)
- NI-32ENHANCING TUMOR RESPONSE USING QUANTITATIVE VOLUMETRY FROM T1 SUBTRACTION MAPS IN MALIGNANT GLIOMA TREATED WITH DENDRITIC CELL VACCINATION (2014) (1)
- Radiation of Potential Local Cancer Stem Cell Niches Improves Survival of Patients With Glioblastoma Multiforme (2012) (1)
- Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio). (2016) (1)
- Abstract CT205: Phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status (2020) (1)
- Autocrine endothelin-3 / endothelin receptor B signaling maintains cellular and molecular properties of tumorigenic glioblastoma stem cells (2011) (1)
- 10 Toca 5: Toca 511 combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma (2018) (1)
- Medical and Neuro-Oncology (2010) (1)
- Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas (2022) (1)
- ACTR-64. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/mTOR INHIBITOR GDC-0084 IN GBM PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE (MGMT) PROMOTER STATUS (2019) (1)
- Fyn and Src are Effectors of Oncogenic EGFR Signaling in Glioblastoma Patients (2009) (1)
- Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. (2017) (1)
- IMCT-04TOCA 5: PHASE 2/3 RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 WITH TOCA FC VERSUS STANDARD OF CARE IN PATIENTS UNDERGOING PLANNED RESECTION FOR RECURRENT HIGH GRADE GLIOMA (NCT02414165). (2015) (1)
- DDEL-07INTRAVENOUS TOCA 511 DELIVERY LEADS TO VIRAL DNA IN RESECTED HGG (2015) (1)
- PEDIATRICS CLINICAL RESEARCH (2010) (1)
- AT-17RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA (2014) (1)
- Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma. (2017) (1)
- A Pharmacokinetic (PK) study of SU-5416 in patients on enzyme-inducing anti-epileptic drugs (EIAED), by the North American Brain Tumor Consortium (2004) (1)
- Omics and Prognostic Markers (2010) (1)
- ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL (2016) (1)
- Medical and Neuro-Oncology (2010) (1)
- Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status. (2020) (1)
- Benefit of MGMT methylation in glioblastoma in relation to hTERT promoter mutation. (2016) (1)
- PATH-17. CORRELATION OF COMMERCIALLY-AVAILABLE QUANTITATIVE MGMT (O-6-METHYLGUANINE-DNA METHYLTRANSFERASE) METHYLATION SCORES AND OVERALL GBM PATIENT SURVIVAL (2017) (1)
- Mr-016. Phase Ii Pilot Study Of Velcade® (bortezomib) In Combination With Temozolomide And Regional Radiation Therapy For Upfront Treatment Of Patients With Newly-diagnosed Glioblastoma Multiforme (2013) (1)
- Reply to B. Freidlin et al. (2013) (1)
- CTNI-38. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED (ND) OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE (2020) (1)
- Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma. (2020) (1)
- BIOM-31. PROGNOSTIC VALUE OF MGMT METHYLATION IN IDH MUTANT GLIOMAS (2020) (1)
- Final results of a phase I trial with the novel anthracycline derivative RTA 744 in patients with primary brain tumors (2007) (1)
- NIMG-25IMPROVED LEAKAGE CORRECTION FOR DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI ESTIMATES OF RELATIVE CEREBRAL BLOOD VOLUME (rCBV) IN HIGH-GRADE GLIOMAS BY ACCOUNTING FOR BIDIRECTIONAL CONTRAST AGENT EXCHANGE (2015) (1)
- ATIM-17. INVESTIGATION OF ANTI-TUMOR CELLULAR IMMUNE RESPONSE ELICITED BY TOCA 511 & TOCA FC THERAPY IN A RECURRENT HGG PHASE 1 TRIAL (2016) (1)
- NCMP-01. SEIZURE CONTROL AFTER INITIAL PRESENTATION IN IDH MUTATED GLIOMA PATIENTS (2017) (1)
- Reply to T.J. Kruser et al. (2016) (1)
- Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess. (2003) (1)
- Quantification of edema reduction using differential quantitative T 2 ( DQT 2 ) mapping in recurrent glioblastoma treated with bevacizumab (2010) (1)
- Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy. (2019) (1)
- NI-21CONTRAST ENHANCED T1 SUBTRACTION MAPS IMPROVE DETECTION OF RESIDUAL TUMOR FOLLOWING RESECTION, REDUCES MEASUREMENT VARIABILITY, AND PREDICTS SURVIVAL AFTER ANTI-ANGIOGENIC THERAPY IN GLIOBLASTOMA (2014) (1)
- Acknowledgement of Reviewers 2012 (2013) (1)
- ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE (2018) (1)
- NI-54HYPERVASCULAR VOLUME ESTIMATED BY COMPARISON TO A LARGE-SCALE CEREBRAL BLOOD VOLUME (CBV) RADIOGRAPHIC ATLAS PREDICTS SURVIVAL IN RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB (2014) (1)
- NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717) (2015) (1)
- Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. (2014) (1)
- CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (2020) (1)
- Reply to F. Felix et al and M.F. Fay et al. (2016) (1)
- Amine-weighted chemical exchange saturation transfer (CEST) MRI in brain tumors. (2022) (1)
- Pilot study of pulse high-dose lapatinib in combination with temozolomide (TMZ) and radiotherapy (RT) for upfront treatment of glioblastoma (GBM). (2014) (1)
- PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA (2019) (1)
- RBTT-11. NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2019) (1)
- ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA (2019) (1)
- Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study (2022) (1)
- Development of an integrated practice unit: Utilizing a lean approach to impact value of care for brain tumor patients. (2016) (1)
- Overview of Arterial Thromboembolic Events (ATEs) in AVAglio, a Randomized, Placebo-controlled Phase III Trial of Bevacizumab, Radiotherapy and Temozolomide (BEV+RT/TMZ) for Newly Diagnosed Glioblastoma (S22.003) (2014) (1)
- Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile? (2021) (1)
- SURG-09RESULTS OF A DOSE ESCALATION TRIAL OF TOCA 511 WITH TOCA FC IN RECURRENT HGG UNDERGOING REPEAT RESECTION. (2015) (1)
- Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results. (2022) (1)
- CTNI-47. PHASE II STUDY OF ABEMACICLIB IN RECURRENT GBM PATIENTS WITH CDKN2A/B LOSS AND INTACT RB (2020) (1)
- ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE. (2017) (1)
- Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma (2020) (1)
- DDIS-17. DEVELOPMENT OF BRAIN-PENETRANT EGFR INHIBITORS FOR CNS MALIGNANCIES (2019) (1)
- 61. Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High-Grade Glioma: Clinical Update, Molecular Analyses, and Proposed Mechanism of Action (2016) (1)
- RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION (2020) (1)
- Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. (2016) (1)
- ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA (2018) (1)
- Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma (2021) (1)
- ACTR-83. BEVACIZUMAB FOR RADIATION-INDUCED PSEUDOPROGRESSION IN ADULT SUPRASELLAR PILOCYTIC ASTROCYTOMA (2017) (0)
- Author Correction: Federated learning enables big data for rare cancer boundary detection (2023) (0)
- IMCT-05COMBINABILITY OF TOCA FC AND TOCA 511 WITH CHEMOTHERAPY AND TARGETED AGENTS (2015) (0)
- NIMG-59. VALIDATION OF QUANTITATIVE VESSEL SIZE IMAGING (VSI) IN HUMAN GLIOMAS USING IMAGE-GUIDED STEREOTACTIC BIOPSIES (2018) (0)
- Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas. (2021) (0)
- NIMG-52. CHARACTERIZATION OF COGNITIVE FUNCTION IN SURVIVORS OF DIFFUSE GLIOMAS USING MORPHOMETRIC CORRELATION NETWORKS (MCN) (2020) (0)
- Neurocognitive Function (NCF) Substudy and Mini-Mental State Examination (MMSE) Results from the Randomized, Placebo-Controlled Phase III AVAglio Trial of Bevacizumab (BEV) Added to Radiotherapy (RT) and Temozolomide (TMZ) for Newly Diagnosed Glioblastoma (S22.002) (2014) (0)
- Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. (2021) (0)
- NIMG-33. VOLUMETRIC TUMOR MEASUREMENTS ARE SUPERIOR TO 2D BIDIRECTIONAL MEASUREMENTS IN THE EVALUATION OF IDH INHIBITION IN DIFFUSE GLIOMAS: EVIDENCE FROM A PROSPECTIVE PHASE I TRIAL OF IVOSIDENIB (2021) (0)
- Abstract 4321: EGFR signaling in glioblastoma regulates the expression of a brain specific isoform ofalphaPIX/Arhgef6to promote invasion (2012) (0)
- Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination (2020) (0)
- Response to Weltman and Fleury Malheiros, re Lassman et al. (2012) (0)
- NIMG-57QUANTITATION OF 18F-DOPA UPTAKE ON PET PREDICTS TUMOR GRADE WITH HIGH SENSITIVITY AND SPECIFICITY IN NEWLY-DIAGNOSED GLIOMA: UCLA EXPERIENCE. (2015) (0)
- Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma. (2023) (0)
- TAMI-48. ENGRAFTMENT PHENOTYPES IN PRECLINICAL MODEL SYSTEMS REVEAL A FUNCTIONAL SUBGROUP OF PATIENT TUMORS DEPENDENT ON THE BRAIN TUMOR MICROENVIRONMENT FOR GROWTH (2020) (0)
- Combined analysis of O 6 -methylguani ne-DNA methyltransferase protein expression and promoter methyl ation provides opti mized prognosticati on of gli oblastoma outcome NEURO- ONCOLOGY (2015) (0)
- Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma (S23.006) (2018) (0)
- CTNI-03. EXTENDED BENEFITS IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA THAT CONTINUOUSLY RECEIVE TOCA FC AFTER TOCA 511 TREATMEN (2021) (0)
- FLT kinetics predict survival in brain tumor therapy (2009) (0)
- Cellular and Molecular Properties of Glioblastoma Stem Cells Autocrine Endothelin-3 / Endothelin Receptor B Signaling Maintains (2011) (0)
- BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI (2021) (0)
- Probabilistic functional diffusion maps ( fDMs ) in human glioblastoma (2011) (0)
- Health-related quality of life (HRQoL) in AVAglio, a randomized, placebo (P)-controlled phase III study of bevacizumab (B), temozolomide (T) and radiotherapy (RI) in patients (pts) with newly diagnosed glioblastoma (GBM) (2013) (0)
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma (2011) (0)
- SURG-10TRANSCRANIAL TOCA 511 FOLLOWED BY TOCA FC IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) (2015) (0)
- SP-02PATTERNS OF END-OF-LIFE CARE FOR PATIENTS WITH GLIOBLASTOMA (2014) (0)
- ACTR-06. THE TOCA 7 STUDY: PHASE 1B STUDY OF TOCA 511, A LIVE GAMMA RETROVIRUS, AND TOCA FC, AN EXTENDED-RELEASE FORMULATION OF 5-FLUOROCYTOSINE COMBINED WITH STANDARD OF CARE IN NEWLY DIAGNOSED HIGH GRADE GLIOMA (NCT02598011) (2016) (0)
- IMMU-28. HIGH-DIMENSIONAL SINGLE CELL CHARACTERIZATION OF THE SYSTEMIC INFLUENCE OF NEOADJUVANT PD-1 BLOCKADE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (2018) (0)
- Treatment of recurrent hgg patients with the retroviral replicating vector Toca 511 and Toca FC gives durable responses and survival lasting 3 years or longer: Immune mechanisms and molecular analyses of tumors (2018) (0)
- NI-6818F-FDOPA PET IN TREATED LOW-GRADE GLIOMAS WITH NON-ENHANCING T2 CHANGES ON MRI IS PROGNOSTIC OF TUMOR PROGRESSION AND OVERALL SURVIVAL. (2014) (0)
- Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI (2022) (0)
- O 6-2 Morphometric study of myelinated fibers in sural nerve of transthyretin familial amyloid neuropathy asymptomatic carriers : back to the archives of the Corino de Andrade Unit (2018) (0)
- TAMI-06. PRECLINICAL MODELS REVEAL BRAIN-MICROENVIRONMENT SPECIFIC METABOLIC DEPENDENCIES IN GLIOBLASTOMA (2020) (0)
- 421TiPPhase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma (2017) (0)
- CELLULAR INVASION, MOTILITY, AND PROLIFERATION LEVEL ESTIMATES (CIMPLE MAPS): APPLICATION TO TEMOZOLOMIDE- AND BEVACIZUMAB-TREATED PATIENTS (2010) (0)
- Prognostic value of 18F-FDOPA PET in patients with treated low-grade gliomas (2010) (0)
- ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE EXCISION REPAIR INHIBITOR) IN BEVACIZUMAB-NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE (2019) (0)
- IMMU-20. SINGLE-CELL RNASEQ OF TUMOR INFILTRATING IMMUNE CELLS FROM NEOADJUVANT ANTI-PD1 TREATED GBM PATIENTS REVEALS GLOBAL TRANSCRIPTIONAL CHANGES AND IMMUNOSUPPRESSIVE ADAPTIVE RESPONSES BY MYELOID CELLS (2020) (0)
- 18F-Fluoro-thymidine kinetics in brain tumors during treatment (2007) (0)
- Prognostic value of MGMT methylation in IDH mutant gliomas (2022) (0)
- Abstract IA20: Phase II study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naïve patients with recurrent GBM (2016) (0)
- Title Stem cell associated gene expression in glioblastoma multiforme : relationship to survival and the subventricular zone Permalink (2010) (0)
- Optimizing management of glioblastoma: Educational impact on clinicians. (2020) (0)
- 621 POSTER A phase I study of combination therapy with AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, and RAD001, a mTOR inhibitor in recurrent GBM patients (2006) (0)
- Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RT) in newly diagnosed glioblastoma : final results from AVAglio (2013) (0)
- QL-05SELF-REPORTED COGNITIVE DIFFICULTIES AND ASSOCIATED MEDICAL CHARACTERISTICS IN PATIENTS WITH ADULT-ONSET GLIOMA (2014) (0)
- Altered amino acid uptake associated with chemotherapy and radiation exposure in subjects with primary brain tumors (2011) (0)
- Local Identifier : 33874 Abstract : Purpose : To compare " standardization , " " Gaussian normalization , " and " Z-score normalization " intensity transformation techniques in dynamic susceptibility contrast magnetic resonance imaging (2012) (0)
- Quantitati ve probabil istic functional diffusion mappi ng i n newly diagnosed gl ioblastoma treated w i th radiochemotherapy (2015) (0)
- Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment (2018) (0)
- The Addition of Bevacizumab (BEV) to Temozolomide (TMZ) and Radiation Therapy (RT) in Newly Diagnosed Glioblastoma (GBM) Improves Progression-Free Survival (PFS) Without Adding to RT Toxicity (2013) (0)
- CBMT-43. INTEGRATED LIPIDOMIC AND MOLECULAR ANALYSIS REVEALS A SUBSET OF GLIOBLASTOMA VULNERABLE TO FERROPTOSIS (2019) (0)
- Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients (2018) (0)
- Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status (2021) (0)
- NIMG-56. PATTERNS FROM DYNAMIC VESSEL SIZE IMAGING OF ARTERIAL AND VENOUS PERFUSION CORRELATES WITH AGGRESSIVENESS AND STRATIFIES 1p19q CO-DELETED FROM NON-CODELETED LOW-GRADE GLIOMAS (2016) (0)
- Brainstem Gliomas: Clinicopathologic Features and a Practical Diagnostic Approach for Pathologists (2013) (0)
- PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION (2018) (0)
- NI-55PARAMETRIC MAPS OF CONTRAST AGENT DIFFUSION USING A NOVEL DIFFUSION-PERFUSION MODEL APPLIED TO DCE-MRI CAN DIFFERENTIATE NON-ENHANCING TUMOR FROM EDEMA IN HUMAN GLIOBLASTOMA (2014) (0)
- ATIM-25. IMMUNOLOGICAL ACTIVATION IN RESPONDING PATIENTS WITH RECURRENT HGG AFTER TREATMENT WITH TOCA 511 & TOCA FC: RESULTS FROM A PHASE 1 TRIAL (2017) (0)
- An Advanced technique for volumetric analysis (2018) (0)
- Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival. (2023) (0)
- BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001. (2020) (0)
- Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks (2022) (0)
- cell context Striking the balance between PTEN and PDK1: it all depends on the (2009) (0)
- The prevalence of favorable PTEN and MGMT biomarker status in 66 glioblastomas (2008) (0)
- RESIDUAL ENHANCING TUMOR VOLUME IS A STRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY : EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS (2016) (0)
- Persistent Restricted Diffusion Abnormalities in bevacizumab-treated Glioma Patients : Relationship to Outcomes χ (2011) (0)
- Cancer Genes and Genomics Autocrine Endothelin-3 / Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells (2011) (0)
- ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS (2018) (0)
- NI-36VALIDATION OF RANO CRITERIA: CONTRIBUTION OF T2/FLAIR ASSESSMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB (2014) (0)
- NIMG-47. VOLUMETRIC ANALYSIS OF PHASE 2 AND 3 TRIALS IN RECURRENT GLIOBLASTOMA TREATED WITH VB-111 WITH OR WITHOUT BEVACIZUMAB OR BEVACIZUMAB MONOTHERAPY (2019) (0)
- NIMG-15. DIFFERENTIATION OF IDH1 MUTANT AND WILD TYPE GLIOMAS USING pH- AND OXYGEN-SENSITIVE MOLECULAR MRI (2018) (0)
- Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI) (2021) (0)
- Abstract 3308: Endothelin 3/endothelin receptor B signaling pathway blockade depletes radio-chemoresistant glioblastoma stem cells (2011) (0)
- 2-Hydroxyglutarate Inhibit s ATP Synthase andmTOR Signaling Graphical (2015) (0)
- Ipilimumab for recurrent glioblastoma (GBM) (P3.131) (2015) (0)
- Viral Therapy for Glioblastoma (2020) (0)
- QOLP-12. EVALUATION OF THE UCLA NEURO-ONCOLOGY PROGRAM PSYCHOSOCIAL PATIENT SCREENING FORM IN IDENTIFYING DEPRESSION, FATIGUE, AND PERCEIVED COGNITIVE FUNCTION IN PATIENTS WITH GLIOMAS (2019) (0)
- NIMG-08. EVALUATING THE APPLICABILITY OF TUMOR PROBABILITY MAPS AS A RESOURCE FOR IMPROVED BRAIN TUMOR SEGMENTATION (2017) (0)
- Integrated Systems and Technologies Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing (2013) (0)
- DDIS-08. DEVELOPMENT OF BRAIN-PENETRANT EGFR INHIBITORS FOR GLIOBLASTOMA (2018) (0)
- A study of neo-adjuvant and adjuvant ofra-vec (VB-111) for treatment of surgically accessible recurrent GBM. (2022) (0)
- Graded functional diffusion maps ( fDMs ) predict survival in recurrent glioblastoma treated with bevacizumab (2010) (0)
- EPIG-11THE IMPLICATION OF CpG island AND SPINT2 HYPERMETHYLATION IN BOTH IDH1 WILD-TYPE AND MUTANT ADULT DIFFUSE GLIOMAS (2015) (0)
- A Molecular Signature to Predict Meningioma Recurrence and Progression (2013) (0)
- SYST-14 CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (DMG) PATIENTS (2022) (0)
- TAMI-26. INVESTIGATING TUMOR MICROENVIRONMENT METABOLIC DEPENDENCIES IN GLIOBLASTOMA (2021) (0)
- 18F-FLT-PET uptake dynamics and overall survival predictions for patients with recurrent high-grade glioma on bevacizumab therapy (2011) (0)
- P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma (2022) (0)
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (2018) (0)
- CTNI-27. MULTI-CENTER, PHASE 2 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND PRELIMINARY EFFICACY OF PAXALISIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH UNMETHYLATED GLIOBLASTOMA (GBM) (2022) (0)
- ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449 (2022) (0)
- NIMG-34. QUANTIFICATION OF GLYCOLYTIC FLUX REDUCTION IN RECURRENT GLIOBLASTOMA AFTER EGFR INHIBITION USING MOLECULAR MR-PET (2022) (0)
- TMIC-19. NEURODEVELOPMENTAL SUBTYPES SHAPE LIPID METABOLIC REPROGRAMMING IN GLIOMAS (2022) (0)
- CBIO-03. A COMPREHENSIVE CHARACTERIZATION OF THE GBM LIPIDOME REVEALS A MOLECULARLY-DEFINED SUB-GROUP WITH HEIGHTENED SENSITIVITY TO FERROPTOSIS (2021) (0)
- TMIC-02. PRE-SURGICAL IMMUNE CHECKPOINT BLOCKADE RESHAPES THE IMMUNE LANDSCAPE AND SPATIAL ARCHITECTURE OF METASTATIC BRAIN TUMORS (2022) (0)
- CTIM-11. SINGLE-CENTER, OFF-LABEL NEOADJUVANT PEMBROLIZUMAB FOR TREATMENT OF RECURRENT GBM AT UCLA (2022) (0)
- Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide (2015) (0)
- NIMG-50. ASSOCIATION BETWEEN SALINITY, ACIDITY, DIFFUSIVITY, AND HYPOXIA IN HUMAN GLIOMAS USING MULTI-NUCLEAR MRI (2022) (0)
- Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials. (2023) (0)
- DDRE-23. A COMPREHENSIVE CHARACTERIZATION OF THE GBM LIPIDOME REVEALS A MOLECULARLY-DEFINED SUB-GROUP WITH HEIGHTENED SENSITIVITY TO LIPID PEROXIDATION INDUCED CELL DEATH (2021) (0)
- RTID-01. ONC108: A RANDOMIZED PHASE 3 STUDY OF ONC201 IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA (2022) (0)
- NIMG-36. VISUALIZATION OF TUMOR HETEROGENEITY AND PREDICTION OF ISOCITRATE DEHYDROGENASE MUTATION STATUS FOR HUMAN GLIOMAS BY USING MULTIPARAMETRIC PHYSIOLOGIC AND METABOLIC MRI (2021) (0)
- EPCO-10. INTRATUMORAL HETEROGENEITY OF ENVIRONMENT-INDUCED EXPRESSION PROGRAMS IN GLIOMA PATIENTS AND DERIVED MODEL SYSTEMS (2021) (0)
- Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials (2017) (0)
- Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas (2021) (0)
- RTID-02. A PHASE 1, SAFETY LEAD-IN AND RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF VORASIDENIB COMBINED WITH PEMBROLIZUMAB IN RECURRENT OR PROGRESSIVE ENHANCING IDH-1 MUTANT ASTROCYTOMAS: TRIAL IN PROGRESS (2022) (0)
- RTID-05. TRIAL IN PROGRESS: DOSE-FINDING STUDY AND EVALUATION OF [177LU]LU-DOTA-TATE IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED GLIOBLASTOMA AND AS A SINGLE AGENT IN RECURRENT GLIOBLASTOMA (2022) (0)
- NIMG-41. PH-WEIGHTED MOLECULAR MRI AS AN EARLY BIOMARKER OF METABOLIC RESPONSE TO IDH INHIBITION IN IDH MUTANT GLIOMAS (2021) (0)
- NIMG-42. DURABLE OVERALL RESPONSE RATE (ORR) TARGETS FOR RECURRENT GLIOBLASTOMA (RGBM) CLINICAL TRIALS BASED ON THE HISTORIC ASSOCIATION BETWEEN ORR AND MEDIAN OVERALL SURVIVAL (MOS) (2022) (0)
- NIMG-44. PROGNOSTIC VALUE OF PH- AND OXYGEN-SENSITIVE MRI IN GLIOMA PATIENTS (2021) (0)
- QOL-12. “I’M JUST LIKE A BASKET FULL OF PROBLEMS”: QUALITATIVE STUDY OF COGNITIVE DYSFUNCTION AND QUALITY OF LIFE IN GLIOMA SURVIVORS (2022) (0)
- NIMG-48. MULTI-ECHO SPIN-AND-GRADIENT ECHO (SAGE) PERFUSION MRI TO EVALUATE BRAIN TUMOR MICROSTRUCTURE AND MICROVASCULATURE (2022) (0)
- The CNS-penetrant EGFR inhibitor, ERAS-801, shows promising nonclinical activity in a CNS metastases model of EGFR mutant NSCLC (2022) (0)
- TMIC-40. TRANSCRIPTOMIC CHARACTERIZATION OF PATIENT GLIOMAS AND DERIVED MODEL SYSTEMS REVEALS ENVIRONMENTAL INFLUENCE ON NEURODEVELOPMENTAL CELLULAR STATES (2022) (0)
- P01.032 Associations of anticoagulant use with outcome in newly diagnosed glioblastoma (2018) (0)
- A 3 D Probabilistic Glioblastoma Multiforme Location Atlas (2004) (0)
- FLT and FDOPA PET kinetics in recurrent brain tumors: A multitracer approach (2012) (0)
- Temporal and Topographical Specificity of Human Intraoperative Optical Intrinsic Signals (1998) (0)
- Multi-tracer PET Imaging Using Deep Learning: Applications in Patients with High-Grade Gliomas (2022) (0)
- NIMG-31. BRAIN CONNECTIVITY PATTERNS CHARACTERIZE COGNITIVE IMPAIRMENT IN LONG-TERM SURVIVORS OF LOW-GRADE GLIOMA (LGG) USING RESTING-STATE FUNCTIONAL MRI (rs-fMRI) (2019) (0)
- NIMG-17. VALIDATION OF DIFFUSION MRI AS AN IMAGING BIOMARKER FOR BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA IN A RANDOMIZED PHASE III TRIAL OF BEVACIZUMAB WITH OR WITHOUT VB-111 (GLOBE) (2020) (0)
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma (2019) (0)
- Books Received (2001) (0)
- Qualitative detection of ceramide and other metabolites in brain tumor by localized correlated spectroscopy (2009) (0)
- TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA (2016) (0)
- Correlation of intratumoral metabolic changes measured with 18F-FDG PET parametric response maps with concentrations of CC-223, a TORC 1/2 kinase inhibitor, in human glioblastoma. (2014) (0)
- Autologous tumor-lysate pulsed dendritic cell vaccination, together with the TLR-7 agonist 5% imiquimod, and serum pro- inflammatory cytokine levels in glioblastoma patients (2008) (0)
- NIMG-54. AMINE CEST MRI, A FAST AMINO ACID AND PH-WEIGHTED MOLECULAR IMAGING TECHNIQUE, CORRELATES WITH 18F-FDOPA PET AND IMAGE-GUIDED BIOPSY IN HUMAN GLIOMA (2016) (0)
- Correlation of FDOPA-PET uptake with proliferative activity and malignancy grade in brain tumors (2009) (0)
- CBIO-27. INTEGRATED FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY IDENTIFIES THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA (2021) (0)
- SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (2017) (0)
- 18F-FLT PET and 18F-FDOPA PET in evaluate treatment response: Identify the best prognostic marker (2013) (0)
- NIMG-34. MULTI-PARAMETRIC MR-PET IMAGING PREDICTS PHARMACOKINETICS AND CLINICAL RESPONSE TO GDC-0084 IN HUMAN RECURRENT HIGH-GRADE GLIOMA (2019) (0)
- CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS (2020) (0)
- PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165) (2016) (0)
- Prediction of survival time using 18F-FLT kinetics and discriminant analysis in recurrent glioma therapy (2009) (0)
- CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (2020) (0)
- PCSM-09PSYCHOSOCIAL AND SYMPTOMATIC SCREENING AMONG PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMORS. (2015) (0)
- NCOG-10. RELATIONSHIP BETWEEN COGNITIVE FUNCTION, MOOD, AND FUNCTIONING IN GLIOMA SURVIVORS (2019) (0)
- GENE-41. EPIGENETIC DOWN-REGULATION OF THE METALLOTHIONEIN FAMILY IN ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS (2017) (0)
- Metabolic tumor volume by 18F-FDOPA PET is predictive of treatment response in patients with recurrent high-grade gliomas on anti-angiogenic therapy as early as 2 weeks after therapy initiation (2012) (0)
- Response to C. Massard et al (2012) (0)
- Acknowledgement of reviewers 2016 and 2017 (2018) (0)
- Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM) (2016) (0)
- ATIM-01. A PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RE-IRRADIATION IN ADULT SUBJECTS WITH TRANSFORMED IDH MUTANT GLIOBLASTOMA (2017) (0)
- Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry (2019) (0)
- EXTH-55. PRECLINICAL EVALUATION OF NT113, A NOVEL IRREVERSIBLE PAN-ErbB INHIBITOR OPTIMIZED FOR CNS BIODISTRIBUTION (2016) (0)
- DDEL-08OVERALL SAFETY AND EFFICACY IN SUBJECTS WITH RECURRENT HGG TREATED ACROSS 2 TOCAGEN STUDIES - PROGNOSTIC FACTORS ASSOCIATED WITH SURVIVAL (2015) (0)
- THER-06. THERAPEUTIC EFFICACY OF RRV-MEDIATED PRODRUG ACTIVATOR GENE THERAPY IN CLINICAL TRIALS OF RECURRENT HIGH-GRADE GLIOMA AND IN MURINE ORTHOTOPIC MODELS OF INTRACEREBRAL GLIOMA AND INTRACEREBELLAR MEDULLOBLASTOMA (2020) (0)
- Mutation in isocitrate dehydrogenase 1 ( IDH 1 ) leads to increased T 2 , ADC and decreased lactate and glutamate in glioblastoma model (2012) (0)
- MPTH-01. ARE MUTATIONS IN MISMATCH REPAIR (MMR) GENES OUR NEXT BIOMARKER OF ALKYLATING AGENT INDUCED HYPERMUTATOR PHENOTYPE? PRELIMINARY RESULTS FROM THE IVY PRECISION TRIAL (2016) (0)
- P05.06 Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status (2019) (0)
- TMOD-03. GLIOMAPDOX: A MOLECULARLY DIVERSE LIBRARY OF DIRECT-FROM-PATIENT ORTHOTOPIC GLIOMA XENOGRAFTS RECAPITULATES INTRATUMOR HETEROGENEITY (2018) (0)
- Proteins and Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. (2015) (0)
- NI-20ADC HISTOGRAM ANALYSIS FOLLOWING RADIOTHERAPY PREDICTS RESPONSE TO ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GBM. (2014) (0)
- NIMG-60. IDH MUTANT GLIOMAS WITH 1p/19q CO-DELETION ARE LESS ACIDIC THAN NON-CO-DELETED GLIOMAS AS MEASURED WITH PH-WEIGHTED AMINE CEST-MRI AND AMINO ACID PET (2019) (0)
- ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA (2019) (0)
- Characterizing malignant transformation in patients with IDH-mutant glioma. (2022) (0)
- TMIC-06. MYELOID POPULATIONS AND THE EFFECT OF NEOADJUVANT PD-1 INHIBITION IN THE GLIOBLASTOMA MICROENVIRONMENT: A SURFACEOMIC AND TRANSCRIPTOMIC DISSECTION AT THE SINGLE-CELL LEVEL (2019) (0)
- CTNI-44. INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/mTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER (2020) (0)
- Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma (2013) (0)
- Improving care coordination for brain tumor patients through value-based care redesign of a virtual integrated practice unit. (2017) (0)
- SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) (2013) (0)
- Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease (2022) (0)
- Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma. (2022) (0)
- NIMG-54. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM BEVACIZUMAB IN RECURRENT GLIOBLASTOMA WITH A LARGE TUMOR BURDEN: EVIDENCE FROM CLINICAL PRACTICE AND A MULTICENTER PHASE 3 TRIAL (2019) (0)
- ACTR-89. KARNOFSKY PERFORMANCE STATUS AND STEROID USE IN PHASE II TRIAL OF BEVACIZUMAB AND TEMOZOLOMIDE FOR UPFRONT TREATMENT OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2017) (0)
- QLIF-09. A FOCUS ON THE PSYCHOSOCIAL NEEDS OF OLDER BRAIN TUMOR PATIENTS (2016) (0)
- 25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC (2018) (0)
- NIMG-49. VALIDATION OF SIMULTANEOUS PH- AND O2-WEIGHTED MOLECULAR MRI USING 18F-FDG PET, IMMUNOHISTOCHEMISTRY, AND BIOENERGETICS (2020) (0)
- CTIM-19. MOLECULAR AND GENETIC DETERMINANTS OF RESPONSE TO PD-1 BLOCKADE IN RECURRENT GLIOBLASTOMA PATIENTS (2020) (0)
- NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143 (2015) (0)
- CBMT-44. COMPREHENSIVE CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY REVEALS THE MOLECULAR BLOCKS RESPONSIBLE FOR RESISTANCE TO CELL DEATH IN GLIOBLASTOMA (2019) (0)
- was pro-Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study 1 (2003) (0)
- The 1994 National Cancer Institute’s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas. (2021) (0)
- Integrated Systems and Technologies : Mathematical Oncology Response Classi fi cation Based on a Minimal Model of Glioblastoma Growth Is Prognostic for Clinical Outcomes and Distinguishes Progression from Pseudoprogression (2013) (0)
- Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life (2022) (0)
- BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA : RETROSPECTIVE ANALYSIS OF AVAglio (2016) (0)
- NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI (2017) (0)
- ATIM-09. CLINICAL TRIAL IN PROGRESS: A STUDY OF NEOADJUVANT AND ADJUVANT VB-111 FOR TREATMENT OF RECURRENT GBM (2019) (0)
- CTIM-25. NEOADJUVANT ANTI-PD1 IMMUNOTHERAPY FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES OF A STAGE 2 SINGLE-ARM EXPANSION COHORT (2022) (0)
- High-Dose Radiation to the Subventricular Zone Does Not Alter the Patterns of Recurrence in GB (2014) (0)
- Bevacizumab (Bev) to reduce the negative impact of glioblastoma (GBM) tumor size on survival from first recurrence. (2017) (0)
- Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (2018) (0)
- NIMG-01. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM ANTI-VEGF MONOTHERAPY IN GLIOBLASTOMA AT FIRST OR SECOND RELAPSE (2017) (0)
- Abstract 447: The IDH1 mutation in human glioblastoma and its effects on epigenetic modification and cell fate selection (2014) (0)
- AMPK suppressed glioma growth by inhibiting lipogenesis, and by synergistically inhibiting mTOR activity with PTEN (2007) (0)
- Tissue expansion maps ( TEMs ) derived from nonlinear registration of serial 3 D MR scans as an imaging biomarker for detecting brain tumor invasion and quantifying tumor response to therapy (2012) (0)
- ATIM-28. A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS (2016) (0)
- CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143 (2015) (0)
- Regulates Acid Metabolism in Cancer by of the Cystine-Glutamate Antiporter xCT. (2017) (0)
- Predicting overall survival of patients with malignant glioma using relative changes in FLT-PET kinetics (2012) (0)
- Monitoring brain tumor therapy with 18F-FLT (2008) (0)
- PATH-16. COMPREHENSIVE GENOMIC PROFILING ACCURATELY DETERMINES 1p19q CODELETION STATUS IN GLIOMAS (2020) (0)
- Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign (2023) (0)
- HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA (2020) (0)
- Decorin Expression Is Associated With Diffusion MR Phenotypes in Glioblastoma (2019) (0)
- CBIO-05. LIPID METABOLIC REPROGRAMMING SENSITIZES A MOLECULARLY-DEFINED SUBSET OF GLIOBLASTOMAS TO FERROPTOSIS (2020) (0)
- TMIC-26. PRECLINICAL MODEL SYSTEMS OF GLIOBLASTOMA REVEAL MICROENVIRONMENTAL PROGRAMS AND DEPENDENCIES IN PATIENT TUMORS (2019) (0)
- NIMG-53. POST-SURGICAL, RESIDUAL ENHANCING TUMOR VOLUME IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS (2017) (0)
- Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation (2022) (0)
- NIMG-24. RANO CRITERIA DETECTS EARLY PROGRESSION SOONER THAN MODIFIED RANO CRITERIA IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2021) (0)
- Retrospective examination of pseudoprogression in IDH mutant gliomas (2023) (0)
- NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143) (2015) (0)
- BI-10pH-WEIGHTED MRI IN HUMAN GLIOMAS (2014) (0)
- Prior Radiation in Subjects Who Were Treated With Toca 511 and Toca FC Across 3 Toca 511 Phase 1 Trials (2016) (0)
- Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. (2023) (0)
- NIMG-84. TUMOR LOCATION IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS. (2017) (0)
- GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE (2015) (0)
- NIMG-45. DIFFUSION MRI AS AN EARLY BIOMARKER OF OVERALL SURVIVAL BENEFIT IN RECURRENT GLIOBLASTOMA TREATED WITH IMMUNE CHECKPOINT INHIBITORS (2021) (0)
- QL-04FACTORS ASSOCIATED WITH SUICIDAL IDEATION IN CLINICALLY DISTRESSED ADULT GLIOMA PATIENTS. (2014) (0)
- Abstract C169: Inhibition of SREBPs by fatostatin reduces glioblastoma cell proliferation and viability. (2011) (0)
- Radiation necrosis versus recurrent tumor: Value of 18F-FDOPA PET in patients with high-grade gliomas (2009) (0)
- NI-22NON-ENHANCING TUMOR RESPONSE USING QUANTITATIVE T2 MAPS PREDICTS SURVIVAL IN GLIOBLASTOMA TREATED WITH BEVACIZUMAB (2014) (0)
- Patient-specific biomathematical model to predict benefit of resection in human gliomas. (2013) (0)
- CBIO-25. INTEGRATED MOLECULAR AND BH3 PROFILING OF THE INTRINSIC APOPTOTIC MACHINERY IDENTIFIES THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA (2020) (0)
- ETMM-02. PRECLINICAL MODELS REVEAL BRAIN-MICROENVIRONMENT SPECIFIC METABOLIC DEPENDENCIES IN GLIOBLASTOMA (2021) (0)
- ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT. (2017) (0)
- Combined Treatment with Dopamine Receptor Antagonists and Radiation Creates a Metabolic Vulnerability in Mouse Models of Glioblastoma (2020) (0)
- 214 Noninvasive Monitoring of Immunotherapeutic Responses in Glioblastoma Using Novel Imaging Techniques (2018) (0)
- A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients (2023) (0)
- ASPM Analysis of oncogenic signaling networks in glioblastoma identifies (2006) (0)
- CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
- NIMG-55. SIMULTANEOUS QUANTITATIVE PH MAPPING AND HYPOXIA IMAGING USING FAST MULTI-ECHO AMINE CEST-EPI IN HUMAN GLIOMAS (2016) (0)
- CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS (2021) (0)
- CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
- ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) (2017) (0)
This paper list is powered by the following services:
Other Resources About Timothy Cloughesy
What Schools Are Affiliated With Timothy Cloughesy?
Timothy Cloughesy is affiliated with the following schools:
